AACR 2023 | A personalized mRNA vaccine with pembrolizumab in melanoma

Jeffrey Weber, MD, PhD, NYU Langone Medical Center, New York, NY, presents findings from the Phase II Keynote-942 trial (NCT03897881) of mRNA-4157, a personalized mRNA vaccine, with pembrolizumab in patients with resected high-risk melanoma. Patients were randomized to receive the vaccine with pembrolizumab or pembrolizumab alone. Relapse-free survival (RFS) was significantly improved in patients receiving the vaccine without a clinically meaningful increase in side effects. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.